Dr. Berchuck is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1364 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-778-1900Fax+1 617-632-2165
Summary
- Dr. Jacob Berchuck is a Medical Oncologist at the Winship Cancer Institute and Assistant Professor of Medical Oncology at Emory University School of Medicine. Dr. Berchuck received his undergraduate and medical degrees from Duke University, trained in Internal Medicine at the University of California San Francisco, and completed a fellowship in Medical Oncology at the Dana-Farber/Mass General Brigham.
In addition to caring for patients with genitourinary malignancies, Dr. Berchuck conducts translational cancer research focused on developing biomarkers to guide treatment decisions, deciphering mechanisms of treatment resistance and discovering novel therapeutic strategies. His research predominantly focuses on “liquid biopsies” – studying tumor biology by profiling cell-free DNA circulating in the bloodstream – aiming for a future where a simple blood draw can provide real-time insights to choose the right treatment for the right patient at the right time.
Dr. Berchuck’s research has resulted in publications in several impact journals including Nature Medicine, Cancer Cell, Annals of Oncology, JAMA Oncology, European Urology, Clinical Cancer Research, Cancer Research, and JCO Precision Oncology.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2020
- University of California (San Francisco)Residency, Internal Medicine, 2013 - 2016
- Duke University School of MedicineClass of 2013
Certifications & Licensure
- MA State Medical License 2017 - 2026
- GA State Medical License 2024 - 2025
- CA State Medical License 2014 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.Daniel Boiarsky, Alok K Tewari, Doga C Gulhan, Ziad Bakouny, Guruprasad Ananda
The Prostate. 2024-12-01 - Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.Rashad Nawfal, Razane El Hajj Chehade, Jacob E Berchuck
Clinical Cancer Research. 2024-11-04 - 2 citationsInsulin resistance during androgen deprivation therapy in men with prostate cancer.Shehzad Basaria, Mary-Ellen Taplin, Marie McDonnell, Donald C Simonson, Alexander P Lin
Cancer. 2024-11-01
Press Mentions
- Addressing Mental Health in Patients with Lung Cancer Improves OutcomesJuly 30th, 2022
- Research Round-up: Lung CancerNovember 18th, 2020
- ASCO GU 2020: Best of Journals Prostate Cancer: SurgeryFebruary 17th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: